https://doi.org/10.4081/monaldi.2021.1617
Single inhaler triple therapy in COPD – all that glitters is not gold
Submitted: September 22, 2020
Accepted: November 30, 2020
Published: April 28, 2021
Accepted: November 30, 2020
Abstract Views: 1170
PDF: 633
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/or improvement of lung function...
Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with Fluticasone furoate/Umeclidinium/Vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020;201:1508-16.
DOI: https://doi.org/10.1164/rccm.201911-2207OC
Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven latin american countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis 2018;13:1545-56.
DOI: https://doi.org/10.2147/COPD.S154097
Buhl R, Criée C-P, Kardos P, et al. Patients in clinical trials on COPD triple therapy compared to real world populations Am J Respir Crit Care Med 2019;199:A1117.
DOI: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1117
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-8.
DOI: https://doi.org/10.1016/S2213-2600(16)00100-4
Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65.
DOI: https://doi.org/10.1378/chest.126.1.59
Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747-8.
DOI: https://doi.org/10.1016/S2213-2600(18)30327-8
Palli SR, Frazer M, DuCharme M, et al. Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. J Manag Care Spec Pharm 2020;26:1363-74.
DOI: https://doi.org/10.18553/jmcp.2020.20159
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;383:35-48.
DOI: https://doi.org/10.1056/NEJMoa1916046
How to Cite
Deshmukh, Kartik, and Arjun Khanna. 2021. “Single Inhaler Triple Therapy in COPD – All That Glitters Is Not Gold”. Monaldi Archives for Chest Disease 91 (2). https://doi.org/10.4081/monaldi.2021.1617.
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- P.E. Van Schil, J.M. Hendriks, M.G. De Maeseneer, P.R. Lauwers, Current management of spontaneous pneumothorax , Monaldi Archives for Chest Disease: Vol. 63 No. 4 (2005): Pulmonary series
- Sabino Scardi, Luca Perazza, Remarks on Angina Pectoris , Monaldi Archives for Chest Disease: Vol. 64 No. 1 (2005): Cardiac series
- Giovanni Gregorio, Rodolfo Citro, Carmine Chieffo, Fabrizio Corsini, Carmine Riccio, Maria Iacomino, Maria Serafino, Epidemiology of Acute Coronary Syndrome in Campania , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- Roberto Carlon, Cardiac Rehabilitation in the Region of Veneto , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- Oscar Serafini, Francesco Greco, Gianfranco Misuraca, Mario Chiatto, Antonino Buffon, Echocardiography in the diagnostic and prognostic evaluation of thromboembolic pulmonary hypertension , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- Daniela Miani, Dario Gregori, Marco Ghidina, Patrizia Rozbowsky, Laura Pilotto, Maria Cecilia Albanese, Claudio Fresco, Paolo Maria Fioretti, The Left Ventricular Dysfunction Questionnaire: Italian translation and validation , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- P.J.P. Poels, T.R.J. Schermer, C. Van Weel, Underuse of spirometry in the diagnosis of COPD , Monaldi Archives for Chest Disease: Vol. 63 No. 4 (2005): Pulmonary series
- Gabriella Malfatto, Giovanna Branzi, Caterina Bizzi, Paola Valli, Mario Facchini, Favourable effects of cardiovascular rehabilitation on funcional capacity and autonomic balance in elderly patients with heart failure , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- Massimo F. Piepoli, Exercise Rehabilitation in Heart Disease: the real “polypill†for primary and secondary prevention , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- R. Trisolini, D. Paioli, V. Fornario, L. Lazzari Agli, D. Grosso, M. Patelli, Collapse of a new type of self-expanding metallic tracheal stent , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
<< < 46 47 48 49 50 51 52 53 54 55 > >>
You may also start an advanced similarity search for this article.
